To further determine the effects of MAPK/ERK pathway involved in Mirk modulating cancer cell survival, the H292 cells were treated with 20 nM siRNAs with/without U0126 in gradient for 72 h followed by western blot and flow cytometry analyses, respevtively. The gene discussed is DYRK1B; the disease is cancer.